Acting Attorney General Todd Blanche on Thursday announced that cannabis products covered by the Food and Drug Administration or licensed for medical use by states will be moved from Schedule I to Schedule III under federal law, a step the Justice Department says will expand research and patient access. The change affects FDA-approved or state-authorized medical marijuana products but does not yet deschedule whole-plant cannabis, and Blanche has scheduled a June hearing to consider a broader reclassification. President Donald Trump directed his administration last year to begin this process; the move comes five days after he signed an executive order aimed at increasing medical access to certain psychedelics. The rule will be published in the Federal Register and could be legally challenged during the 30-day window before it could take effect.
Key Takeaways
- The Justice Department moved FDA-covered or state-licensed marijuana products from Schedule I to Schedule III, aligning them with drugs such as codeine-containing pain relievers in federal classification.
- Acting AG Todd Blanche announced a rule-making process and set a public hearing for June to consider reclassifying all marijuana more broadly.
- Since 1970 marijuana has been listed as Schedule I, defined as having high abuse potential and no accepted medical use; this action reverses that federal classification for certain products.
- The change is expected to ease federal restrictions on research and may alter how clinicians and researchers access cannabis-derived medicines.
- The new rule, once published in the Federal Register, has a 30-day countdown before taking effect but is likely to face legal challenges that could delay implementation.
- Industry issues such as federal tax treatment and banking for cannabis businesses remain tied to broader federal law and will not be resolved by this rescheduling alone.
- Advocacy groups say the adjustment is a meaningful step but stop short of full descheduling; polls cited by advocates indicate more than two-thirds of Americans favor full legalization.
Background
Federal law has treated marijuana as a Schedule I controlled substance since the Controlled Substances Act of 1970, a designation that signals a ‘high potential for abuse’ and ‘no currently accepted medical use.’ Over the past five decades, a majority of U.S. states have enacted laws permitting medical or recreational use, producing a complex patchwork of state-level legalization that conflicts with federal prohibition. The conflicting regimes have created practical problems for businesses, including limitations on access to federal banking services and unfavorable federal tax treatments under Section 280E. The Biden administration launched a review of marijuana’s federal status in 2022, and the Department of Health and Human Services later recommended a change; the DEA in 2024 sought hearings but postponed them indefinitely at that time.
President Trump directed his administration last year to pursue rescheduling to expand research and clinical access, and his recent executive order on psychedelics signaled broader interest in reforming controls on certain psychoactive substances. Rescheduling a drug narrows the gap between federal scheduling and state laws for specific products but does not automatically harmonize regulatory, tax or banking rules across jurisdictions. Legal and political debates over full federal legalization versus regulated reclassification are ongoing, with advocates pushing for descheduling and opponents urging caution on public health grounds.
Main Event
On Thursday, Acting Attorney General Todd Blanche signed an administrative order that moves cannabis products covered by FDA approval or authorized under state medical programs to Schedule III. The Justice Department framed the change as a way to enable more comprehensive research into safety and efficacy and to give clinicians clearer information about treatment options. Blanche also announced a formal rule-making process and set a hearing for June to consider whether all marijuana should be reclassified beyond the limited product category affected by this order. The Justice Department noted that the rule, once published, will be subject to public comment and potential litigation during the 30-day period before it could take effect.
The reclassification places those cannabis-derived products alongside medications such as acetaminophen with codeine, altering prescribing and oversight frameworks under federal law. The order explicitly leaves intact federal criminal prohibitions that apply to unsanctioned marijuana distribution and does not change state-level regulatory regimes, which will continue to govern retail access where state law permits. Administration officials said the measure is aimed first at improving the research pathway for patients and doctors rather than immediately resolving commercial or banking restrictions that affect cannabis firms. Legal experts contacted by reporters predicted swift legal challenges from parties that oppose or seek broader reform, which could keep the status quo in place for months or years depending on court actions.
The announcement followed a presidential directive last year and came days after the White House took separate steps on psychedelics, signaling an administration willing to reconsider federal scheduling across a range of substances. The Department of Justice emphasized the narrow scope of the administrative move while opening a formal process to weigh broader changes, a procedural approach that allows for public input and judicial review. State officials and industry representatives said they will monitor the June hearing and potentially submit comments or petitions during the rule-making stage.
Analysis & Implications
Rescheduling FDA-approved and state-licensed cannabis products to Schedule III is likely to ease some federal research barriers, including tighter controls on storage, transport and approvals that accompany Schedule I substances. Researchers routinely contend with burdensome registration and security requirements for Schedule I studies; a Schedule III designation reduces those hurdles and could accelerate clinical trials and data collection on therapeutic uses. If more clinical evidence emerges, it may increase pressure on lawmakers and regulators to reconsider broader regulatory frameworks, but gaining conclusive evidence will still require time, funding and institutional coordination.
For patients, a Schedule III classification could mean expanded access to standardized, FDA-regulated cannabis-derived medications where providers feel more comfortable prescribing them. However, everyday access for patients in state-legal programs is unlikely to change immediately because state dispensary systems operate under their own laws. Cannabis businesses seeking banking access and federal tax relief will still face obstacles because many of those issues derive from the plant’s federal criminal status as a controlled substance and from statutory tax provisions that target drug trafficking profits.
Politically, the move recalibrates federal posture without settling the larger question of legalization. The administration’s step may appeal to constituencies that favor enhanced medical research while leaving more contentious issues—recreational legalization, regulatory frameworks, criminal-justice reforms—to legislative debate. Courts will likely be a central battleground if stakeholders challenge the rule, and any prolonged litigation would delay the anticipated benefits for research and clinical practice. Internationally, the U.S. position affects treaty obligations and can influence other countries’ policies, but a limited rescheduling of certain products is less likely to trigger immediate shifts in global drug-control arrangements.
Comparison & Data
| Characteristic | Schedule I (Marijuana) | Schedule III (Rescheduled products) |
|---|---|---|
| Federal classification since | 1970 | Varies by drug; newly affected products moved in 2026 |
| Medical acceptance | Federal: ‘no accepted medical use’ (historically) | Recognized medical uses where FDA approval exists |
| Regulatory burden for research | High (stringent registration, storage rules) | Lower (easier approvals, fewer security constraints) |
| Example drugs | Heroin (Schedule I) | Codeine-containing medications (Schedule III) |
The table highlights how the reclassification narrows federal restrictions for specified products, chiefly by reducing research controls and opening a clearer clinical pathway. It does not equate to removing criminal penalties for unsanctioned marijuana cultivation or distribution under federal law. Stakeholders should view the change as an administrative step with operational benefits for research and regulated medical products rather than as a resolution of the legal status of the broader cannabis marketplace.
Reactions & Quotes
Justice Department officials characterized the move as fulfilling the president’s directive to broaden medical access and research.
This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.
Acting Attorney General Todd Blanche / U.S. Department of Justice (official statement)
Advocates and reform groups welcomed the step but emphasised it falls short of full federal legalization; they said the change creates an opportunity for more serious policy conversations.
Moving cannabis out of Schedule I lets policymakers have policy conversations that don’t start and end with that definition.
Morgan Fox / National Organization for the Reform of Marijuana Laws (advocacy)
Legal analysts warned that the rule is likely to be contested in court and that implementation could be delayed even after publication in the Federal Register.
Any rule of this kind typically faces prompt legal challenges that can pause implementation for months to years.
Independent legal analyst (summary of expert commentary)
Unconfirmed
- A full timetable for when broader reclassification of all marijuana might take effect is not yet confirmed; the June hearing opens a process but does not set final dates.
- Predicted impacts on federal banking and tax rules for cannabis businesses remain speculative until further administrative or legislative changes are taken.
- The precise scope of products that will ultimately be moved out of Schedule I beyond FDA-covered or state-licensed items is not finalized and depends on the rule-making record and potential legal challenges.
Bottom Line
The Justice Department’s move to shift certain cannabis-derived products from Schedule I to Schedule III is a meaningful administrative step that lowers federal barriers to research and reframes regulatory debates, but it stops short of legalizing marijuana at the federal level. Patients and researchers may benefit from reduced paperwork and clearer pathways to clinical study, yet many commercial and financial problems tied to federal prohibition—banking, taxes, and criminal statutes—will persist unless further action is taken by regulators or Congress. The June hearing and the likely legal challenges will determine how quickly, and how broadly, these changes translate into practical effects. Observers should treat this as a procedural opening for more extensive reform rather than a final settlement of the cannabis question.
Sources
- BBC News (news report)
- U.S. Department of Justice (official agency)
- NORML (advocacy organization)
- Drug Enforcement Administration (federal regulator)